Latest news with #Alamar
Korea Herald
7 hours ago
- Health
- Korea Herald
Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort
NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 to Power Biomarker Discovery in 23,000 Longitudinal Samples FREMONT, Calif., July 29, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced a strategic collaboration with the German Center for Neurodegenerative Diseases (DZNE) to deploy its ultra-sensitive NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 in the Rhineland Study—one of the world's most comprehensive and innovative longitudinal aging cohorts, as well as in some of the DZNE's clinical disease specific cohorts. This initiative will profile 23,000 plasma samples to accelerate biomarker discovery and advance understanding of healthy aging and neurodegeneration. "Understanding aging and dementia requires both advanced technology and deeply characterized cohorts," said Prof. Monique Breteler, Director of Population Health Sciences at DZNE and Principal Investigator of the Rhineland Study. "Integrating Alamar's multiplex panels into our research opens new opportunities to decode the molecular signatures of brain aging." The DZNE Rhineland Study is an ongoing, large-scale population-based cohort designed to investigate determinants of healthy aging and the development of neurodegenerative diseases across the lifespan. By utilizing Alamar's NULISAseq CNS Disease Panel 120, researchers will be able to measure hundreds of brain-related proteins from minimal blood volumes, with exceptional sensitivity and specificity. Notably, the CNS panel's ability to distinguish brain-derived phosphorylated tau from total phosphorylated tau in plasma represents a transformative advance for early detection and risk stratification of neurodegenerative conditions such as Alzheimer's disease. In addition, the NULISAseq Inflammation Panel 250 provides the most comprehensive and sensitive profiling of immune-related proteins implicated in aging and neuroinflammation associated with neurodegenerative diseases. The resulting proteomic data will be combined with the study's extensive clinical, demographic, and imaging datasets, enabling researchers to track protein changes over time, identify early biomarkers, and support the development of precision diagnostics and targeted therapies. "This partnership marks a major step forward in aging and dementia research," said Yuling Luo, PhD, Founder, Chairman and CEO of Alamar Biosciences. "With NULISA's unmatched sensitivity and the depth of the DZNE Rhineland Study, we can uncover novel protein biomarkers that reveal the trajectories of cognitive health and disease progression in aging populations." This collaboration reflects a shared commitment to scientific rigor, inclusivity, and innovation in neurodegenerative disease research. By capturing diverse aging trajectories in a deeply characterized population, Alamar and DZNE aim to drive earlier diagnosis, improved prognosis, and new therapeutic pathways for age-related brain disorders. About the DZNE Rhineland Study The DZNE (German Center for Neurodegenerative Diseases) Rhineland Study is an ambitious, population-based cohort following thousands of individuals across decades to uncover determinants of healthy aging and neurodegeneration. Detailed clinical, imaging, genetic, and lifestyle data are collected and harmonized to enable deep insights into the aging brain. Learn more about the DZNE at and about the DZNE Rhineland Study at About Alamar Biosciences, Inc. Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit
Cision Canada
7 hours ago
- Health
- Cision Canada
Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort
NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 to Power Biomarker Discovery in 23,000 Longitudinal Samples FREMONT, Calif., July 29, 2025 /CNW/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced a strategic collaboration with the German Center for Neurodegenerative Diseases (DZNE) to deploy its ultra-sensitive NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 in the Rhineland Study—one of the world's most comprehensive and innovative longitudinal aging cohorts, as well as in some of the DZNE's clinical disease specific cohorts. This initiative will profile 23,000 plasma samples to accelerate biomarker discovery and advance understanding of healthy aging and neurodegeneration. "Understanding aging and dementia requires both advanced technology and deeply characterized cohorts," said Prof. Monique Breteler, Director of Population Health Sciences at DZNE and Principal Investigator of the Rhineland Study. "Integrating Alamar's multiplex panels into our research opens new opportunities to decode the molecular signatures of brain aging." The DZNE Rhineland Study is an ongoing, large-scale population-based cohort designed to investigate determinants of healthy aging and the development of neurodegenerative diseases across the lifespan. By utilizing Alamar's NULISAseq CNS Disease Panel 120, researchers will be able to measure hundreds of brain-related proteins from minimal blood volumes, with exceptional sensitivity and specificity. Notably, the CNS panel's ability to distinguish brain-derived phosphorylated tau from total phosphorylated tau in plasma represents a transformative advance for early detection and risk stratification of neurodegenerative conditions such as Alzheimer's disease. In addition, the NULISAseq Inflammation Panel 250 provides the most comprehensive and sensitive profiling of immune-related proteins implicated in aging and neuroinflammation associated with neurodegenerative diseases. The resulting proteomic data will be combined with the study's extensive clinical, demographic, and imaging datasets, enabling researchers to track protein changes over time, identify early biomarkers, and support the development of precision diagnostics and targeted therapies. "This partnership marks a major step forward in aging and dementia research," said Yuling Luo, PhD, Founder, Chairman and CEO of Alamar Biosciences. "With NULISA's unmatched sensitivity and the depth of the DZNE Rhineland Study, we can uncover novel protein biomarkers that reveal the trajectories of cognitive health and disease progression in aging populations." This collaboration reflects a shared commitment to scientific rigor, inclusivity, and innovation in neurodegenerative disease research. By capturing diverse aging trajectories in a deeply characterized population, Alamar and DZNE aim to drive earlier diagnosis, improved prognosis, and new therapeutic pathways for age-related brain disorders. About the DZNE Rhineland Study The DZNE (German Center for Neurodegenerative Diseases) Rhineland Study is an ambitious, population-based cohort following thousands of individuals across decades to uncover determinants of healthy aging and neurodegeneration. Detailed clinical, imaging, genetic, and lifestyle data are collected and harmonized to enable deep insights into the aging brain. Learn more about the DZNE at and about the DZNE Rhineland Study at About Alamar Biosciences, Inc. Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit
Cision Canada
a day ago
- Health
- Cision Canada
Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer's Association International Conference (AAIC)
Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at International Meeting FREMONT, Calif., July 28, 2025 /CNW/ -- Alamar Biosciences, a company pioneering precision proteomics to drive the earliest detection of disease, today announced the presentation of NULISA™ data in over 30 scientific sessions and poster presentations at the AAIC conference held July 27-31 in Toronto, Canada. The NULISA platform is poised to redefine the landscape of biomarker detection, offering unprecedented sensitivity, specificity and multiplex detection for neurodegenerative disease diagnosis and monitoring. This year's AAIC marks the first public presentation of robust clinical data generated using NULISA to measure brain-derived pTaus alongside over 120 key CNS disease-related proteins, an achievement that could accelerate both early detection and therapeutic monitoring in Alzheimer's and related neurodegenerative conditions. "The presentation of brain-derived pTau data at AAIC is a testament to the power of the NULISA sensitivity and specificity and our team's dedication to advancing biomarker development for neurodegenerative diseases," said Yuling Luo, PhD, Founder, Chairman and CEO of Alamar Biosciences. These data will be presented during Alamar's product theater on Monday, July 28, 1:20 PM ET, featuring Prof. Jonathan Schott from University College London and the UK DRI, and Dr. Cheryl Wellington from the University of British Columbia. Highlights include: Brain-Derived pTau Performance: The presentation will showcase data from the 1946 Birth Cohort featuring the new brain-derived pTau isoforms using the NULISAseq™ CNS Disease Panel 120 in both presymptomatic and post-AD diagnosis samples, highlighting the superior ability of brain-derived pTaus to predict Alzheimer's disease years before it was diagnosed Correlations with Disease Progression: Data will demonstrate the correlation between brain-derived pTau levels and amyloid and Tau PET imaging Biomarkers for neuropathologies and AD co-pathologies: Analysis of a unique cohort of patients with autopsy-confirmed pathologies with the NULISAseq™ CNS Disease Panel 120 identified biomarkers for detecting neuropathologies and AD co-pathologies. Preclinical research: The NULISAseq™ Mouse Panel 120 demonstrated utility in analysis of plasma and brain homogenate samples from multiple clinical models of AD. The Alzheimer's Association International Conference (AAIC) is the world's premier forum for the scientific community focused on dementia and Alzheimer's research. Every year, the conference gathers leading experts, scientists, clinicians, and stakeholders to share the latest discoveries, foster collaborations, and accelerate the quest for effective diagnostics and therapies. See here for a full list of posters and presentations featuring NULISA data during the AAIC meeting. About Alamar Biosciences, Inc. Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit
Korea Herald
a day ago
- Health
- Korea Herald
Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer's Association International Conference (AAIC)
Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at International Meeting FREMONT, Calif., July 28, 2025 /PRNewswire/ -- Alamar Biosciences, a company pioneering precision proteomics to drive the earliest detection of disease, today announced the presentation of NULISA™ data in over 30 scientific sessions and poster presentations at the AAIC conference held July 27-31 in Toronto, Canada. The NULISA platform is poised to redefine the landscape of biomarker detection, offering unprecedented sensitivity, specificity and multiplex detection for neurodegenerative disease diagnosis and monitoring. This year's AAIC marks the first public presentation of robust clinical data generated using NULISA to measure brain-derived pTaus alongside over 120 key CNS disease-related proteins, an achievement that could accelerate both early detection and therapeutic monitoring in Alzheimer's and related neurodegenerative conditions. "The presentation of brain-derived pTau data at AAIC is a testament to the power of the NULISA sensitivity and specificity and our team's dedication to advancing biomarker development for neurodegenerative diseases," said Yuling Luo, PhD, Founder, Chairman and CEO of Alamar Biosciences. These data will be presented during Alamar's product theater on Monday, July 28, 1:20 PM ET, featuring Prof. Jonathan Schott from University College London and the UK DRI, and Dr. Cheryl Wellington from the University of British Columbia. Highlights include: The Alzheimer's Association International Conference (AAIC) is the world's premier forum for the scientific community focused on dementia and Alzheimer's research. Every year, the conference gathers leading experts, scientists, clinicians, and stakeholders to share the latest discoveries, foster collaborations, and accelerate the quest for effective diagnostics and therapies. See here for a full list of posters and presentations featuring NULISA data during the AAIC meeting. About Alamar Biosciences, Inc. Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit
The Star
22-04-2025
- Sport
- The Star
AI only just beginning to revolutionise the NBA game
NEW YORK: It's not a scene out of the future, but a reality on the hard courts of today. Using artificial intelligence, a top basketball team found the right defensive strategy that made the difference to win the NBA championship. Data specialist Rajiv Maheswaran declines to name the outfit that leveraged AI analysis to victory, saying in a corporate video only that it happened several years ago. That was "the moment that sealed it", added the co-founder of tech startup Second Spectrum, which provides the league with swathes of player positioning data gathered during crucial games. Analytics have transformed the NBA over the past decade, with AI and other breakthroughs still ramping up. Embryonic in the early 2000s, the revolution truly took hold with motion-capture cameras installed in every venue in 2013. Ten years later, new tech upgraded renderings of the court from 2D to 3D, unlocking even more precious data. Cameras track 29 points for each player "so you know not just where they are, but you know where their elbow is, and you know where their knee is", said Ben Alamar, a sports analytics writer and consultant. "You're actually able to see, yes, that was a high quality (defensive) closeout," said Tom Ryan, head of Basketball Research and Development at the NBA, describing an often-used manouvre. "It's adding more context to that metric." "Now all 30 teams are doing significant analysis with varying levels of success," said Alamar. Houston, Golden State and Oklahoma City were often cited among early adopters at the turn of the 2010s. This season, Oklahoma City is on top of regular season standings, "and they play different," said ESPN Analytics Group founder Dean Oliver. "They force turnovers, and they have very few turnovers themselves. So there are definitely advantages to be gained." "It's not going to turn a 25-win team into a 70-win team during the season, but it can turn a 50-win team into a 55, 56-win team," according to Alamar. AI allows for "strategic insights" like "understanding matchups, finding the situations where players perform well, what combinations of players," he added. 'Optimising shots' None of the dozen teams contacted by AFP agreed to discuss their work on analytics. "Teams are (understandably) secretive," Oliver confirmed. Even before 3D, motion capture data was already shifting the game, taking basketball from a more controlled pace to something looser and faster, he added. The data showed that faster play secures more open looks and a higher percentage of shots – a development that some criticise. On average, three-point shot attempts have doubled over the last 15 years. "As a league now, we look deep into analytics," Milwaukee point guard Damian Lillard noted at February's All-Star Game. While it perhaps "takes away the originality of the game... you've got to get in line with what's working to win." The league is taking the issue seriously enough that Commissioner Adam Silver recently mentioned that "some adjustments" could be made to address it. Even now, AI has "plenty of upside" yet to emerge, said Oliver. "The data is massive, but converting that into information, into knowledge that can be conveyed to players, that they can absorb, all of those steps are yet to be done." 'Get calls right' The league itself is pursuing several analytics and AI projects, including for real-time refereeing. "The ROI (return on investment) is very clear," said Ryan. "It's about getting more calls right, faster and in a transparent way to our fans." "We would love a world where if a ball goes out of bounds and you're not sure who it went off of, rather than going to replay you look at high frame rate video in real time with 99.9% accuracy... That's really our North Star." Spatial data can also extend the fan experience, shown off during the recent "Dunk the Halls" Christmas game between San Antonio and New York. An alternative telecast rendered the game in video game-style real-time display, with avatars replacing live action images. "We want to experiment with all different types of immersive media," says Ryan. "We just want to be able to sell our game and present it in compelling ways." – AFP
